Kornimate/medical-research-clean huggingface dataset:
observational study of durvalumab in patients with non-small-cell lung cancer in the united kingdom

Conditions: Non-Small Cell Lung Cancer NSCLC

Summary: this is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with locally advanced, unresectable stage iii non-small cell lung cancer receiving durvalumab in the united kingdom (the codak study). physicians who have treated patients who have locally advanced, unresectable stage iii nsclc with durvalumab will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws. data from this study will provide uk-specific real-world data on patients receiving durvalumab through the early access programme (eap) or post-reimbursement.

primary objectives the primary study objectives, in patients with locally advanced, unresectable stage iii nsclc treated with durvalumab as part of the uk eap or non-eap, are: 1. to describe clinical outcomes 2. to describe the patient demographic and clinical characteristics secondary objective 1. to describe treatment patterns of durvalumab

Eligibility criteria:
inclusion criteria: * patient has documented diagnosis of locally advanced, unresectable stage iii nsclc * patient has received platinum-based crt and received ≥1 dose of durvalumab * patient was initiated on durvalumab (index event) between 1st september 2017 and 31st december 2019 via the eap or non-eap * patient was aged ≥18 years at durvalumab initiation exclusion criteria: * patients who participated in the pacific-r study * participation in any clinical study with an investigational product at the time of durvalumab initiation or during the observational period

Keywords: nsclc unresectable stage iii
utility of acupuncture in the treatment of postoperative nausea and vomiting in ambulatory surgery

Conditions: Postoperative Nausea and Vomiting

Summary: to evaluate the utility of acupuncture in the treatment of postoperative nausea and vomiting (ponv) in ambulatory surgery.

prospective, randomized, comparative study. the disease to be studied is postoperative nausea and vomiting (ponv). ponv, described by some as "the big little problem", has a great impact on patient´s satisfaction and the postoperative care needed. considering the increase of outpatient surgery there is an expanding demand for effective ponv treatment to prevent delays in discharge or unplanned readmissions. the estimated annual costs of ponv in the u.s. per year are 100 million dollars. approximately 75 million patients are anesthetized in the world annually. it is estimated that 20-30% of these patients experience ponv, reaching 80% in patients at high risk. this incidence of ponv has maintained despite the improvement in surgical and anesthetic techniques and advances in antiemetic pharmacology. increasingly, acupuncture is becoming part of western medicine as a complementary treatment. acupuncture has been described to effectively reduce the symptoms of different diseases, including ponv.

Eligibility criteria:
inclusion criteria: * patients of both sexes, aged 18 years and older. * asa i-ii patients who will undergo a surgical procedure under general anesthesia in an ambulatory setting. * patients who are anticipated to not require admission to the recovery room or intensive care unit. * patients who, according to clinical criteria of the acupuncturist physician, are likely to benefit from acupuncture. * patients with a sufficient educational level to complete the health questionnaires required in the study. * patients who have given their written informed consent to participate in the study. exclusion criteria: * patients with any pathology that under medical discretion makes their participation in the study inadvisable. * patients who cannot respond to the questionnaires provided during the study. * patients with known hypersensitivity to the materials of the ear seeds.

Keywords: ponv acupuncture
long-term effects of torso-weighting

Conditions: Multiple Sclerosis

Summary: the goal of this pilot study is to test the protocol for investigating the longer-term effects of torso weighting on physical activity, number of falls, and muscle activation (when muscles turn on and off and how intensely) in five volunteers with multiple sclerosis. the hypotheses of this study include: torso weighting will (1) increase physical activity, (2) decrease the number of falls, and (3) improve the timing and coordination of muscle activation during balance perturbations.

torso weighting, using the balance-based torso-weighting (bbtw) method, is an intervention that addresses balance by first challenging stability in standing using a series of perturbations (nudges) and resisted rotations to people. challenging stability allows the assessor to determine directional instability. once the direction of instability is determined, small weights are placed on a vest-like garment and retesting of balance occurs. in this study, participants will be tested with no weights (nw), with sham weights (sw), and with bbtw weighting (wt). following non-weighted baseline assessment, participants will be randomly allocated into the sham weight condition or bbtw weight condition in a cross-over design. the initial condition (nw) will last four weeks and the final two conditions (sw,wt) will last two weeks each. following each condition, outcome measures will be reassessed. throughout the study, participants will be asked to wear a commercially-available remote monitoring device (e.g., fitbit flex) and keep a daily log of physical activity and number of falls. during the sw and wt conditions, participants will wear the assigned garment for 2-4 hours daily.

Eligibility criteria:
inclusion criteria: * self-reported a diagnosis of multiple sclerosis * self-reported mild or moderate gait or balance difficulties * living in the community rather than in a care facility * able to walk independently for at least one minute at a time with or without an assistive device * no exacerbations within the past 2 months * able to get to the testing area and tolerate 2-3 hours of testing for each assessment occasion * willing to be nudged by a researcher when standing exclusion criteria: * unable to comprehend and follow instructions in english * current diagnosis of other neurological disorders such as head injury, stroke, parkinson disease, or other conditions that affect gait or balance (self-reported) * experiencing pain that could be exacerbated by external perturbation while standing * history of skin reaction to adhesives

Keywords: balance-based torso-weighting physical activity neurorehabilitation
prevalence and trends of antimicrobial resistance of helicobacter pylori in korea

Conditions: Helicobacter Pylori Infection; Helicobacter Pylori Associated Gastrointestinal Disease; Helicobacter Pylori Infection, Susceptibility to; Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation

Summary: to assess antimicrobial resistance rates and minimal inhibitory concentrations in h. pylori isolated from patients with upper gastrointestinal disease with long-term period.

failure of eradication treatment against helicobacter pylori (h. pylori) is mainly caused by antimicrobial resistance. however, there is no relevant studies have been conducted on the prevalence and trend of antimicrobial resistance, which is considered to have a major determinant of eradication failure. in addition, studying the trend of resistance rate is an important basis for establishing an appropriate strategy for eradication treatment in the future. patients who had h. pylori colonies isolated from culture were consecutively enrolled from 2003. from each patient, 1 to 10 h. pylori isolates were isolated. trends in mic distribution and prevalence of resistance were investigated for each antimicrobial agent according to time period. antimicrobi resistances suspected to related with failure of empirical ppi triple, quadruple, and rescue fluoroquinolone-containing treatment were also investigated. multiple resistance, which is simultaneously resistant to various antibiotics, will also be investigated. risk factors for the antibiotic resistance will be analyzed.

Eligibility criteria:
inclusion criteria: * subjects who had a h. pylori infection and had consented to undergo culture analysis via endoscopic resection, in order to determine the minimal inhibitory concentration (mic) of various antibiotics. exclusion criteria: * patients with a concurrent critical illness, who abused drugs or alcohol, who were pregnant or nursing, or those who had received antibiotics, ppis, or bismuth salts within 4 weeks, were excluded.

Keywords: eradication rescue therapy antibiotics resistance helicobacter pylori
vitamin d effects in overweight patients

Conditions: Overweight; Obesity

Summary: the purpose of the study is to investigate in overweight patients who are on a telemedically guided weight loss program the influence of a daily vitamin d supplement on * weight loss and body composition, * selected inflammation markers and biochemical parameters of lipid and glucose metabolism . * selected clinical parameters such as blood pressure, heart rate

obese patients are known to have low levels of vitamin d metabolites. there is some evidence that vitamin d and/or dietary calcium may influence energy metabolism and body weight. we therefore perform a prospective controlled trial with 200 overweight (body mass index 27-29.9 kg/m2) and obese subjects (body mass index \>= 30 kg/m2) who are on a telemedically guided weight loss program. subjects randomly receive a daily vitamin d supplement or a placebo for 1 year. participants have to send their body weight data to the study office weekly. in addition, a nutritionist at the study office has to be contacted weekly to receive further support concerning the weight loss program. dietary records have to be completed monthly. clinical parameters and blood samples are collected at baseline, and after 6 and 12 months. it is the aim of the study to investigate the vitamin d effects on weight loss and body composition. in addition, possible vitamin d effects on clinical and selected biochemical parameters should be assessed. these parameters include heart rate, blood pressure, inflammation markers, and parameters of lipid and glucose metablolism.

Eligibility criteria:
inclusion criteria: * body mass index \> 27 kg/m2 exclusion criteria: * pregnant and lactating women * vegetarians * patients with renal insufficiency (creatinine \> 1.5 mg/dl) * history of renal stones and gallstones * patients with insulin dependent diabetes mellitus * parallel participation in another clinical study * missing informed consent * subjects with pacemaker implantation

Keywords: body weight body compostion vitamin d blood pressure
evaluation of the adhesion to the genepy network

Conditions: Hereditary Cancer Syndrome; Hereditary Breast and Ovarian Cancer; Hereditary Colorectal Endometrial Cancer Syndrome

Summary: in order to best meet the needs of all those affected by the genetic risk of cancer in our region, it is important to identify the factors likely to influence the course leading to the genepy surveillance network. the aim of this study is to evaluatie the adhesion to the network of care of people at genetic risk of cancer in midi-pyrénées (genepy).

this network has been open since november 2015 for people who are genetically predisposed to breast / ovarian cancer. the extension to digestive pathologies (hnpcc syndrome, paf) is in progress. it concerns not only the persons carrying a mutation also those belonging to a family without identified mutation but whose risk of predisposition is important. the genepy network is based on a collaboration between oncogenetic consultations in the region and professionals practicing in institutions (private, public) and liberal: general practitioners, gynecologists, radiologists, oncologists, gastroenterologists, psychologists ... it is therefore a multicentric and multidisciplinary network, which aims to promote the local care of people genetically predisposed (or considered at high risk of genetic predisposition), while ensuring a high level of competence, to guarantee an optimal and equitable care on the whole of midi pyrenees. the diagnosis of a new genetic disease in an individual is likely to have implications for other family members who may themselves be at risk of developing the disease and / or passing it on to their children. the inclusion of subjects in the genepy network follows the genealogical study of a case (index) : relatives are identified as potentially at risk. in accordance with the recommendations, but also generally at the wish of the patients, the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. if these people reside in the midi pyrenees toulouse oncogenetic consultation is open to them. if following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the genepy network for their monitoring.

Eligibility criteria:
inclusion criteria: * people with an identified mutation, predisposing to tumors of the breast / ovary or colon / rectum * people resident in the midi-pyrénées region exclusion criteria: * people under 18

Keywords: breast hereditary cancer ovarian predisposition
mental coaching and counseling for bipolar patients: dealing with moments of crisis in times of covid-19.

Conditions: To Determine the Incidence of Depression in Subjects Affected by Bipolar Disorder

Summary: the goal of this interventional study is to evaluate some outcome parameters at the time of enrollment (t0), during the treatment (t1 and t2) and at the end (t3) of the subjects who will have carried out an individual counseling intervention or mental coaching. the aim is to determine the incidence of depression, trait anxiety, state anxiety, sleep disorders, resilience, defense mechanisms, distress caused by stressful events in a sample of subjects affected by bipolar disorder.


Eligibility criteria:
inclusion criteria: * recruited subjects have a diagnosis of bipolar disorder and are 18 years of age or older. exclusion criteria: * previous or current intellectual disability in accordance with the diagnostic and statistical manual of mental disorders, dsm-5. * patients who are unable to express consent and who do not have a caregiver who can give it for them.
brain structural abnormalities in patients with vertigo

Conditions: Vertigo; MRI

Summary: introduction: dizziness is one of the most common complaints in medical practice and is associated with various underlying conditions, including neurological, otolaryngological, and psychological disorders. preliminary imaging studies like ct, cervical spine x-rays, and carotid/vertebral artery ultrasound, aids in precise diagnosis and targeted therapeutic decisions. mri is one of the most effective imaging modalities currently available for examining the brain. purpose: to identify structural brain changes linked to vertigo, explore pre-mri diagnostic approaches, and evaluate treatment strategies. methods: the study included 232 patients with vertigo and 232 control subjects. mri results were categorized, and pre-mri examinations, symptoms, and treatments were analyzed. statistical comparisons were conducted using chi-square and t-tests, with significance set at p\<0.05.

vertigo is a prevalent symptom with multiple underlying etiologies, including neurological, vascular, and musculoskeletal causes. despite its high prevalence, the exact structural brain abnormalities associated with vertigo remain unclear. this observational study aims to assess brain mri findings in patients with vertigo and compare them to a control group without vertigo symptoms. the study also evaluates pre-mri diagnostic procedures, such as vertebral/carotid ultrasound and cervical spine x-rays, to identify potential vascular and musculoskeletal contributors to vertigo. the results may provide insights into the structural brain changes linked to vertigo and help refine diagnostic and treatment strategies.

Eligibility criteria:
inclusion criteria: * age ≥18 years * reported dizziness (vertigo) as a primary symptom * brain mri requested by the attending physician exclusion criteria: * prior neurological disease or disorder (other than vertigo/dizziness in the vertigo group) * mri contraindications (e.g., pacemaker, metal implants, claustrophobia)

Keywords: vertigo mri white matter lesions circle of willis sinusitis bppv lifestyle modifications betahistine
chidamide for refractory/relapsed peripheral t cell lymphoma

Conditions: Peripheral T Cell Lymphoma

Summary: this trial intends: 1.to evaluate the concentration of chidamide in the serum and cerebral-spinal fluid of ptcl patients at certain time points after taking the medicine, to evaluate the pharmacokinetics of chidamide in these patients and its cns (central nervous system) distribution. 2. to evaluate the efficiency and safety of chidamide in ptcl patients.


Eligibility criteria:
inclusion criteria: 1. ptcl patients confirmed by histopathology examination. 2. did not accept radiotherapy, chemotherapy, targeted-therapy or hematopoietic stem cell transplantation within 4 weeks prior to inclusion; 3. age 18-75 years old, male or female; 4. ecog: 0-1 point; 5. body weight: male 67±20 kilograms (47-87 kg), female 55±20 kilograms (35-75 kg); 6. blood-routine test should satisfy (except lymphoma-related abnormalities): hb≥90g/l，anc≥1.5×109/l，plt≥90×109/l； 7. estimated survival ≥ 3 months; 8. willing to sign the written consent before the trial. exclusion criteria: 1. women during pregnancy or lactation, or fertile women unwilling to take contraceptive measures. 2. qtc elongation with clinical significance (˃ 480ms), ventricular tachycardia, atrial fibrillation, cardiac conducting blockage, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease that requires treatment. 3. cardiac b ultrasound show end-diastolic pericardial dark zone≥ 10mm 4. patients who have received organ transplantation. 5. patients received symptomatic treatment for bone marrow toxicity within 7 days prior to enrollment. 6. patients with active hemorrhage. 7. patients with or with history of thrombosis, embolism, cerebral hemorrhage, or cerebral infarction. 8. patients with active infection, or with continuous fever within 14 days prior to enrollment. 9. had major organ surgery within 6 weeks prior to enrollment. 10. impaired liver function ( total bilirubin ˃ 1.5 times of normal maximum, alt/ast˃ 2.5 times of normal maximum, for patients with infiltrative liver disease alt/ast ˃ 5 times of normal maximum), impaired renal function (serum creatinin˃ 1.5 times of normal maximum). 11. patients with mental disorders or those do not have the ability to consent; 12. patients with drug abuse, long term alcoholism that may impact the results of the trial.
computer vision syndrome visual sequelae

Conditions: Computer Vision Syndrome

Summary: the university students will respond to cvs-f3 survey form and then they will be subjected to complete ophthalmic examination and investigations

cvs-f3 is a survey form consisted of up to 30 questions regarding computer vision syndrome (cvs) complains, thereafter a randomized sample of students will be subjected to complete ophthalmic examination including visual acuity and refractive measurements, intraocular pressure measurements, slitlamp and fungus examinations, mferg examinations. the sudents will be requested to decrease their screen time and the examinations will be repeated one month later.

Eligibility criteria:
inclusion criteria: - university students exclusion criteria: * amblyopia * anisometropia * strabismus * previous eye surgery
efficacy and safety of pitavastatin in a real-world setting

Conditions: Hypercholesterolemia

Summary: the prospective, observational, non-comparative trial in south korea was designed to evaluate the efficacy and safety of pitavastatin (livalo) in clinical practice in 28,343 patients.

this study was conducted in 893 facilities in korea from 2 apr 2012 to 1 apr 2017. this study was designed to administer 1mg, 2mg, or 4mg pitavastatin to patients with hyperlipidemia at the age of 20 or older for at least 8 weeks.

Eligibility criteria:
inclusion criteria: * patients in need of statin treatment who are taking or are planning to take livalo tablets, or who are taking other statins or are planning to change to livalo tablets. exclusion criteria: * patients with hypersensitivity to pitavastatin * patients with active liver disease or untranslated transaminase levels patients with a constant rise in * patients with severe liver failure or biliary obstruction and patients with cholestasis * patients who are receiving cyclosporine * myopathy patients * pregnant women or women of childbearing age and lactating women * children * patients with genetic problems, such as galactose intolerance, lapp lactose deficiency or glucose-galactose * patients deemed inappropriate by the investigator

Keywords: pitavastatin livalo safety data south korea large-scale prospective trial
effect of polyphenols on peripheral vascular disease.

Conditions: Peripheral Arterial Disease

Summary: peripheral arterial disease (pad) is a clinical setting characterized by an exceptionally high risk for cardiovascular events. oxidative stress seems to play a role in impairing flow-mediated dilation (fmd) and contributing to atherosclerosis in patients with pad. cocoa seems to exert artery dilatation via oxidative stress inhibition. objectives: to investigate whether in pad patients, dark chocolate elicits artery dilatation via down-regulation of nox2, the catalytic core of nadph oxidase.

atherosclerosis represents the major cause of worldwide death; it is a complex phenomenon that encompasses the intricate interplay of classic cardiovascular risk factors, oxidative stress and inflammation. peripheral artery disease (pad) is a clinical setting that well represents the model of widespread atherosclerosis. pad affects 20% of patients over the age of 75. furthermore, pad patients are at an exceptionally high risk for cardiovascular events and the majority will eventually die of a cardiac or cerebrovascular etiology. polyphenol could represent a novel therapeutic strategy to counteract atherosclerosis. during the last decades, a growing interest in polyphenols resulted from prospective and epidemiological studies that showed the beneficial effects of these substances on human health. in particular, polyphenols exert their beneficial effect by inhibition of nadph oxidase (nox2), an enzyme directly involved in atherosclerosis; thus, the activation of this enzyme leads to an enhanced production of oxidative stress and inflammatory processes. the objective of this study is to evaluate the effect of polyphenols on oxidative stress and inflammation and on surrogate markers of atherosclerosis in pad patients. polyphenols, inhibiting nox2-mediated oxidative stress and immune-mediated process, could represent a novel therapy to reduce the high risk of cardiovascular events in pad.

Eligibility criteria:
inclusion criteria: every pad patient to be enrolled in the study had: 1. claudication (defined as leg pain on walking, disappearing within 10 minutes of standing, of presumed atherosclerotic origin) and 2. ankle/brachial index (abi), that was assessed as ankle/arm systolic blood pressure ratio by doppler ultrasonography \<0.90 on the worst leg at rest. patients had to be in stable conditions without abrupt changes of abi (\>20%) in the last month before the enrolment. exclusion criteria: subjects were excluded from the study if they had liver insufficiency, serious renal disorders (serum creatinine\>2.8 mg/dl), acute stroke, acute myocardial infarction, deep venous thrombosis or if they were current smokers or were taking antioxidants.

Keywords: peripheral arterial disease oxidative stress cocoa polyphenols nadph oxidase